HONZ(SZ:300086)2025-01-23 10:08Financial Projections - The estimated net loss for 2024 is projected to be between 154 million and 226 million RMB, compared to a profit of 11.53 million RMB in the same period last year, representing a decline of 1,435.66% to 2,060.12%[3] - The estimated loss after deducting non-recurring gains and losses is projected to be between 151 million and 222 million RMB, compared to a profit of 13.56 million RMB in the same period last year, indicating a decline of 1,213.69% to 1,737.35%[3] - The impact of non-recurring gains and losses on net profit is estimated to be approximately -3.6 million RMB[6] - The financial data presented in the earnings forecast is preliminary and unaudited, with final figures to be disclosed in the 2024 annual report[7] Revenue Decline - The decline in revenue is attributed to inventory destocking in respiratory products and a decrease in terminal sales volume[5] Market Competition - Increased competition in the pharmaceutical terminal market has led the company to enhance sales investment to expand market share and marketing channels[5]